Mavacamten Poised to Expand to Pediatric Obstructive Hypertrophic Cardiomyopathy

(MedPage Today) -- NEW ORLEANS -- The benefit of mavacamten (Camzyos) held up in symptomatic adolescents with obstructive hypertrophic cardiomyopathy (HCM), the phase III SCOUT-HCM trial showed. Already available to adults, the cardiac myosin...
Source
MedPage Today
Opens original article in a new tab



